Regorafenib Price in Pakistan | Registered as Regonix 40 mg

Description

Regonix (Regorafenib) 40 mg Tablets:

Regonix is the trade-name formulation of regorafenib, manufactured by Beacon Pharma, available in 40 mg film-coated tablets.

These tablets are intended for oral administration under the supervision of an oncology specialist. The current listed price in Pakistan is approximately PKR 255,000 for a pack of 28 tablets.

Regorafenib belongs to the class of multi-kinase inhibitors. It works by blocking multiple protein kinases that are involved in tumour growth, metastasis, angiogenesis (development of new blood vessels feeding the tumour), and the tumour micro-environment.

For patients whose disease has progressed despite prior appropriate therapies, Regonix can offer a further treatment option.

When taken, the typical schedule (depending on indication) is an oral dose once daily for 21 consecutive days followed by a 7-day break (i.e., a 28-day cycle) until tumour progression or unacceptable toxicity.

Prior to initiation and during therapy, close monitoring of liver function tests, blood pressure, wound healing, cardiac status, and other parameters is mandatory given its toxicity profile.

Because of the high cost and potential for serious adverse effects, its use must be carefully weighed in a multidisciplinary oncology setting.

Regorafenib (Regonix) Uses:

Regorafenib (Regonix) is indicated (under specialist supervision) for:

• Metastatic colorectal cancer (mCRC) in adult patients who have already received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.

• Advanced gastrointestinal stromal tumours (GIST) after failure of imatinib and sunitinib. NCBI

• Hepatocellular carcinoma (HCC) in adult patients previously treated with sorafenib. NCBI

• Off-label or emerging uses may exist in other tumour types under investigational settings (consult a specialist).

Side Effects of Regorafenib (Regonix):

Common / Less Severe

Examples include:

• Diarrhoea, nausea, stomach pain. Drugs.com

• Loss of appetite, weight loss. Cleveland Clinic

• Fatigue, weakness. Drugs.com

• Hand-foot skin reaction (palmar-plantar erythrodysesthesia) – redness, swelling or pain in palms/soles. WebMD

• Increased blood pressure (hypertension). Drugs.com

• Mouth or throat inflammation (mucositis), change in voice (hoarseness). PMC

Serious / Life-Threatening

• Hepatotoxicity: severe liver injury, jaundice, dark urine, elevated liver enzymes. NCBI

• Gastrointestinal perforation or fistula (a hole in stomach/intestine). WebMD

• Bleeding/haemorrhage (internal bleeding, bleeding gums, etc). Drugs.com

• Poor wound healing (particularly if recent surgery). Mayo Clinic

• Cardiac ischemia/infarction, hypertension crisis, reversible posterior leukoencephalopathy syndrome (rare). FDA Access Data

Key Monitoring/Precautions

• Avoid grapefruit/grapefruit juice (can increase drug levels). Mayo Clinic

• Use effective contraception for both men and women during and for at least 2 months after finishing therapy. Drugs.com

• Ensure normal liver and cardiac baseline; monitor regularly.

• Pause or discontinue before surgery (2 weeks or as directed) because of wound healing risk. Mayo Clinic

Comparison Table – Regorafenib vs Similar Medications

Below is a comparative overview of Regonix (regorafenib) versus two other medications used in similar settings (metastatic colorectal cancer, later lines) for easier reference. This is not exhaustive, and use decisions should always involve the oncology specialist.

Key takeaways from the comparison:

• While regorafenib shows clear benefit in refractory settings, it is associated with a comparatively high toxicity burden. PubMed

• TAS-102 and fruquintinib present alternative options with somewhat different safety profiles; choice depends on patient fitness, prior treatments, and local regulatory/availability context.

• Cost, availability (especially in Pakistan), and patient preference/monitoring capacity are important practical considerations.

Important Notes & Disclaimers

• This product description and table are not a prescription or substitute for a full clinical decision. The decision to use Regonix (regorafenib) requires a qualified oncology specialist, full assessment of patient health status, prior treatments, comorbidities and monitoring capabilities.

• The price listed (PKR 255,000 for 28 tablets) is indicative; actual cost may vary by region, hospital/clinic, import taxes, and availability.

• The side-effect listing is not exhaustive. Individual risk varies.

• For any off-label use, dosage modification, treatment interruption or monitoring, follow the specialist’s guidance and local regulatory labeling.

• In Pakistan, the availability of specialist supportive care (monitoring liver function, blood pressure, side-effect management) is critical given the toxicity profile of this class of drugs.